STAIR VIII
Stroke Treatment Academic Industry Roundtable


March 9-10, 2013
Washington D.C.
 

"Accelerating the Evolution of Stroke Therapy"

 

Presentation Slides

 

MISSION, GOALS AND OBJECTIVES OF STAIR VIII

Introduction - STAIR VIII Chairman: Greg Albers

SESSION 1 - UPDATE ON ENDOVASCULAR REPERFUSION TRIALS

What did we learn from IMS III? – Joe Broderick
Imaging-based Studies: MR Rescue, DEFUSE 2, TNK, DIAS – Chelsea Kidwell
What do SWIFT and TREVO 2 tell us about stent-trevors – Raul Nogueira
Study designs and endpoints in ongoing endovascular trials –  Wade Smith

SESSION 2 - STROKE IMAGING RESEARCH ROADMAP (STIR)

Defining salvageable tissue and collaterals – Mark Parsons
Imaging of recanalization and reperfusion – Andrew Demchuk
Imaging based selection for clinical trials – Ken Lees
Clinical translation of advanced imaging techniques for stroke – Ona Wu

SESSION 3 - NEW ORAL ANTICOALGULANTS: UNRESOLVED ISSUES AND NEXT STEPS

IV tPA in the 3-4.5 hour window: data analysis and US regulatory submission – Susan Begelman, Genentech
Regulatory Challenges for Endovascular Trials – Stacey Pugh, Covidien Neurovascular
Current FDA Expectations for Endovascular Trials – Larry Rodichok,  FDA-CDRH
Oral Anticoagulants: New Regulatory Considerations – Marty Rose, FDA-CDER

NINDS PRESENTATIONS

The NINDS Stroke Research Planning Effort – Results and Implementation - Story Landis, NINDS Director
Stroke Network - Walter Koroshetz, NINDS Deputy Director

RECOMMENDATION DEVELOPMENT WORKSHOPS